Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with or Without Comorbid Diabetes

Clinical Therapeutics

Volumn 37, Issue 6, 2015, Pages 1195-1205

  Ascher Svanum, Haya ^a   Chen, Yun Fei ^a   Hake, Ann ^a   Kahle Wrobleski, Kristin ^a   Schuster, Dara ^a   Kendall, David ^a   Heine, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

clinical trial; cognition; diabetes; functioning; Key words Alzheimer disease; quality of life

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITION ASSESSMENT; COGNITIVE DEFECT; COMORBIDITY ASSESSMENT; DAILY LIFE ACTIVITY; DIABETES MELLITUS; EXPLORATORY RESEARCH; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); COGNITION; COGNITION DISORDERS; DISEASE COURSE; PSYCHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84931004209     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.01.002     Document Type: Article

References (43)

1. J. Janson, T. Laedtke, and J.E. Parisi Increased risk of type 2 diabetes in Alzheimer disease Diabetes 53 2004 474 481 10.2337/diabetes.53.2.474
2. T.P. Knowles, M. Vendruscolo, and C.M. Dobson The amyloid state and its association with protein misfolding diseases Nat Rev Mol Cell Biol 15 2014 384 396 10.1038/nrm3810
3. J.P. Ryan, D.F. Fine, and C. Rosano Type 2 diabetes and cognitive impairment: contributions from neuroimaging J Geriatr Psychiatry Neurol 27 2014 47 55 10.1177/0891988713516543
4. G.J. Biessels, I.J. Deary, and C.M. Ryan Cognition and diabetes: a lifespan perspective Lancet Neurol 7 2008 184 190 10.1016/S1474-4422(08)70021-8
5. T. Cukierman, H.C. Gerstein, and J.D. Williamson Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies Diabetologia 48 2005 2460 2469 10.1007/s00125-005-0023-4
6. E.W. Gregg, K. Yaffe, J.A. Cauley Osteoporotic Fractures Research Group Is diabetes associated with cognitive impairment and cognitive decline among older women? Arch Intern Med 160 2000 174 180 10.1001/archinte.160.2.174
7. A. Ott, R.P. Stolk, and F. van Harskamp Diabetes mellitus and the risk of dementia: the Rotterdam study Neurology 53 1999 1937 1942 10.1212/WNL53.9.1937
8. R.O. Roberts, D.S. Knopman, and Y.E. Geda Association of diabetes with amnestic and nonamnestic mild cognitive impairment Alzheimers Dement 10 2014 18 26 10.1016/j.jalz.2013.01.001
9. G.J. Biessels, S. Staekenborg, and E. Brunner Risk of dementia in diabetes mellitus: a systematic review Lancet Neurol 5 2006 64 74 10.1016/S1474-4422(05)70284-2
10. K. Akter, E.A. Lanza, and S.A. Martin Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71 2011 365 376 10.1111/j.1365-2125.2010.03830.x
11. A.M. Moloney, R.J. Griffin, and S. Timmons Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling Neurobiol Aging 31 2010 224 243 10.1016/j.neurobiolaging.2008.04.002
12. E.C. McNay, and A.K. Recknagel Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes Neurobiol Learn Mem 96 2011 432 442 10.1016/j.nlm.2011.08.005
13. S. Craft, L.D. Baker, and T.J. Montine Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial Arch Neurol 69 2012 29 38 10.1001/archneurol.2011.233
14. L. Egefjord, M. Gejl, and A. Møller Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - protocol for a controlled, randomized double-blinded trial Dan Med J 59 2012 A4519
15. D.S. Geldmacher, T. Fritsch, and M.J. McClendon A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease Arch Neurol 68 2011 45 50 10.1001/archneurol.2010.229
16. M. Gold, C. Alderton, and M. Zvartau-Hind Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study Dement Geriatr Cogn Disord 30 2010 131 146 10.1159/000318845
17. S. Artero, M.L. Ancelin, and F. Portet Risk profiles for mild cognitive impairment and progression to dementia are gender specific J Neurol Neurosurg Psychiatry 79 2008 979 984 10.1136/jnnp.2007.136903
18. W. Xu, B. Caracciolo, and H.X. Wang Accelerated progression from mild cognitive impairment to dementia in people with diabetes Diabetes 59 2010 2928 2935 10.2337/db10-0539
19. B. Winblad, K. Palmer, and M. Kivipelto Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment J Intern Med 256 2004 240 246 10.1111/j.1365-2796.2004.01380.x
20. C. Carlson, K. Sundell, and W. Estergard Efficacy of solanezumab in patients with mild or moderate Alzheimer's disease: pooled analyses findings from two phase III studies [abstract] Alzheimers Diment 9 4 suppl 2013 139 10.1016/j.jalz.2013.04.082
21. J.L. Cummings, R. Doody, and C. Clark Disease-modifying therapies for Alzheimer disease: challenges to early intervention Neurology 69 2007 1622 1634 10.1212/01.wnl.0000295996.54210.69
22. R.S. Doody, R. Raman, and M. Farlow A phase 3 trial of semagacestat for treatment of Alzheimer's disease N Engl J Med 369 2013 341 350 10.1056/NEJMoa1210951
23. R.S. Doody, R.G. Thomas, and M. Farlow Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321 10.1056/NEJMoa1312889
24. R.C. Mohs, D. Knopman, and R.C. Petersen Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 suppl 2 1997 S13 S21 10.1097/00002093-199700112-00003
25. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198 10.1016/0022-3956(75)90026-6
26. D. Galasko, P.R. Kershaw, and L. Schneider Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease J Am Geriatr Soc 52 2004 1070 1076 10.1111/j.1532-5415.2004.52303.x
27. P. Kind The EuroQoL Instrument: an index of health-related quality of life B. Spilker, Quality of Life and Pharmacoeconomics in Clinical Trials 2nd ed 1996 Lippincott-Raven Philadelphia, PA 191 201
28. R.G. Logsdon, L.E. Gibbons, and S.M. McCurry Assessing quality of life in older adults with cognitive impairment Psychosom Med 64 2002 510 519 10.1097/00006842-200205000-00016
29. L. Thorgrimsen, A. Selwood, and A. Spector Whose quality of life is it anyway? The validity and reliability of the Quality of Life-Alzheimer's Disease (QoL-AD) scale Alzheimer Dis Assoc Disord 17 2003 201 208 10.1097/0002093-200310000-00002
30. H. Doruk, M.I. Naharci, and E. Bozoglu The relationship between body mass index and incidental mild cognitive impairment, Alzheimer's disease and vascular dementia in elderly J Nutr Health Aging 14 2010 834 838 10.1007/s12603-010-0113-y
31. M.M. Mielke, P.B. Rosenberg, and J. Tschanz Vascular factors predict rate of progression in Alzheimer disease Neurology 69 2007 1850 1858 10.1212/01.wnl.0000279520.59792.fe
32. M. Musicco, K. Palmer, and G. Salamone Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors J Neurol 256 2009 1288 1295 10.1007/s00415-009-5116-4
33. C. Sanz, S. Andrieu, and A. Sinclair Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease Neurology 73 2009 1359 1366 10.1212/WNL.0b013e3181bd80e9
34. H. Liu-Seifert, E. Siemers, and K. Sundell Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia J Alzheimers Dis 2014 10.3233/JAD-140792 [Epub ahead of print]
35. L.B. Zahodne, J.J. Manly, and A. Mackay-Brandt Cognitive declines precede and predict functional declines in aging and Alzheimer's disease PLoS One 8 2013 e73645 10.1371/journal.pone.0073645
36. C.M. Sanz, H. Hanaire, and B.J. Vellas Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real.FR cohort Diab. Med 29 2012 541 548 http://dx.doi.org/10.1111/j.1464-5491.2011.03445.x
37. C. Hölscher First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease Alzheimers Dement 10 1 suppl 2014 S33 S37 10.1016/j.jalz.2013.12.006
38. G.J. Francis, J.A. Martinez, and W.Q. Liu Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy Brain 131 Pt 12 2008 3311 3334 10.1093/brain/awn288
39. P.L. McClean, and C. Hölscher Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease Neuropharmacology 76 Pt A 2014 57 67 10.1016/j.Neuropharm.2013.08.005
40. J. Tang, Y. Pei, and G. Zhou When aging-onset diabetes is coming across with Alzheimer disease: comparable pathogenesis and therapy Exp Gerontol 48 2013 744 750 10.1016/j.exger.2013.04.013
41. B. van Harten, J. Oosterman, and D. Muslimovic Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus Age Ageing 36 2007 164 170 10.1093/ageing/afl180
42. P.K. Crane, R. Walker, and E.B. Larson Glucose levels and risk of dementia N Engl J Med 369 2013 1863 1864 10.1056/NEJMc1311765
43. G.S. Watson, B.A. Cholerton, and M.A. Reger Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study Am J Geriatr Psychiatry 13 2005 950 958 10.1176/appi.ajgp.13.11.950